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Abstract
Scarring of the skin is a large unmet clinical problem that is of high patient concern and impact. Wound healing is complex
and involves numerous pathways that are highly orchestrated, leaving the skin sealed, but with abnormal organization and
composition of tissue components, namely collagen and proteoglycans, that are then remodeled over time. To improve
healing and reduce or eliminate scarring, more rapid restoration of healthy tissue composition and organization offers a
unique approach for development of new therapeutics. A synthetic collagen-binding peptidoglycan has been developed
that inhibits matrix metalloproteinase-1 and 13 (MMP-1 and MMP-13) mediated collagen degradation. We investigated the
synthetic peptidoglycan in a rat incisional model in which a single dose was delivered in a hyaluronic acid (HA) vehicle at
the time of surgery prior to wound closure. The peptidoglycan treatment resulted in a significant reduction in scar tissue at
21 days as measured by histology and visual analysis. Improved collagen architecture of the treated wounds was
demonstrated by increased tensile strength and transmission electron microscopy (TEM) analysis of collagen fibril diameters
compared to untreated and HA controls. The peptidoglycan’s mechanism of action includes masking existing collagen and
inhibiting MMP-mediated collagen degradation while modulating collagen organization. The peptidoglycan can be
synthesized at low cost with unique design control, and together with demonstrated preclinical efficacy in reducing
scarring, warrants further investigation for dermal wound healing.
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Introduction
Scarringoftheskin,anecessarycomponentofthehealingprocess,
can have a significant psychological and aesthetic impact on a
patient. Dermal scarring occurs as a result of deep dermal wounds
such as those with surgical incisions, traumatic avulsions, or burn
injuries, yet there are currently no products that have produced
consistent results in regenerating healthy dermal tissue and
preventing excessive scar tissue formation. By understanding the
structural and biochemical differences between healthy tissue and
the scar tissue that results from wounding, new therapeutics can be
developed that reduce or prevent scarring.[1] The present work has
taken such an approach by developing a synthetic collagen-binding
peptidoglycan therapeutic (DS-SILY), which targets collagen fibril
organization to restore elements of healthy tissue and shows promise
as a new approach for inhibiting scarring in adult skin.
In nature, decorin is the most abundant proteoglycan (PG) found
in adult skin.[2,3] It is a member of the small leucine rich PGs
(SLRPs) and consists of a collagen-binding protein core attached to
a dermatan sulfate (DS) glycosaminoglycan (GAG) side chain. The
mechanism in which decorin influences skin architecture and
wound healing is multi-faceted, and includes a well-known role in
binding to collagen and influencing its organization.[4–8] Decorin
binds to collagen via its protein core, and functions to modulate
collagen fibrillogenesis and the distribution of fibril diameters.[8–
10] Multiple studies have examined the roles of decorin or its
absence in skin architecture and wound healing (Table 1). In
decorin knockout mice, collagen fibrils have irregular outlines and
have a widedistribution ofdiameters, unlikethe relatively consistent
collagen fibril diameters of healthy skin.[10,11] These knockout
mice have fragile skin and exhibit impaired dermal healing.[9–11]
Another example of impaired or abnormal healing correlating with
decorin deficiency is in hypertrophic scarring; decorin is present in
early stages of hypertrophic scar tissue at levels only 25% that of
normal healthy tissue.[2]
Collagen organization within tissues and in tissue engineered
matrices is a critical parameter that affects cellular behavior.[12] In
fact modulating collagen organization using collagen-binding
peptides alone may improve healing by regulating collagen fibril
diameter and thus enhancing the tensile strength of the skin.[13,14]
Incorporating the DS GAG chain of decorin may further improve
healing through its host of biochemical activities.[15] For example,
DS binds and promotes function of fibroblast growth factors 2 and
10 (FGF-2, FGF-10), which promotes the proliferation of cells that
function in response to injury.[16,17] In addition to its role in
biochemical signaling, the negatively charged DS also provides a
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water loss and restoring homeostasis to the scar.[14]
Decorin also plays a critical role in the balance of inflammation,
collagen synthesis, and collagen degradation, which are critical
parameters in the healing process. Recent work has shown that
decorin can protect collagen fibrils from collagenase degrada-
tion.[18] Collagenases are members of the matrix metalloprotei-
nase (MMP) family, which are upregulated during wound healing
and can initiate the degradation of mature fibrillar type I collagen,
which may increase scarring.[19,20] Additionally, decorin has
been shown to bind to and lower transforming growth factor beta
(TGFb) levels in wounded tissue, attenuating the inflammatory
response and decreasing scar formation.[21–27]
There is strong evidence that decorin plays a critical role in
tissue healing, however decorin is difficult to isolate from animal
tissues and to manufacture, so clinical investigation of decorin in
wound healing is limited.[27,28] We have therefore developed a
synthetic collagen-binding peptidoglycan, modeled after decorin,
which contains a collagen-binding peptide attached to the
biochemically-active DS GAG chain. Unlike decorin, the synthetic
peptidoglycan is highly tailorable and can be manufactured with
relative ease.[5] Like decorin, the synthetic peptidoglycan has been
shown to modulate collagen architecture in vitro, and through its
binding to collagen, can act as physical barrier to platelet adhesion
and subsequent activation.[5,29] Here we further investigate the
function of the synthetic peptidoglycan by demonstrating its ability
to inhibit MMP mediated collagen degradation and mitigate
dermal scarring in a rodent model of dermal wound healing.
Materials and Methods
Reagents
Peptide RRANAALKAGELYKSILYGC (SILY) was purchased
from Genscript (Piscataway, NJ). Dermatan sulfate (DS) and
periodate oxidized DS (oxDS) (41kDa and 6.85% sulfur) were
purchased from Celsus Laboratories (Cincinnati, OH). Crosslinker
PDPH (3-[2-Pyridyldithio]propionyl hydrazide) was purchased
from Pierce (Rockford, IL). Hyaluronic acid (HA) 5 mg/mL,
MW.1 *10
6 Da (Hycoat) was purchased from Neogen (Lex-
ington, KY). Rat tail collagen was purchased from BD Biosciences
(Bedford, MA). MMPs were purchased from R&D Systems
(Minneapolis, MN). All other supplies were purchased from
VWR (West Chester, PA) or Sigma-Aldrich (St. Louis, MO) unless
otherwise noted.
Peptidoglycan synthesis
Peptidoglycan DS-SILY was synthesized as previously de-
scribed.[5] Briefly, oxDS was coupled to the heterobifunctional
crosslinker PDPH forming DS-PDPH. Excess PDPH was removed
by size-exclusion chromatography and DS-PDPH was reacted
with peptide SILY yielding the collagen-binding synthetic
peptidoglycan DS-SILY. The peptidoglycan was separated from
excess free peptide by size exclusion chromatography using MilliQ
running buffer. DS-SILY was lyophilized and stored at 220uC
until further testing.
In vitro collagen degradation
Collagen degradation studies were performed as previously
described by Geng and colleagues, and according to the
manufacturer’s instructions for the MMPs.[18] Collagen was
diluted to 0.4 mg/mL in 10 mM HCl and was diluted in equal
volumes with TES buffer (N-[tris(hydroxymethyl)methyl]-2-ami-
noethanesulfonic acid, 2-[(2-hydroxy-1,1 bis(hydroxymethyl)ethy-
l)amino]ethanesulfonic acid) and vortexed thoroughly to mix.
Fibrils were precipitated by incubating 1 hr at 37uC, and were
then pelleted by centrifuging at 12,000 rpm for 1 minute. The
supernatant was removed and the pellet resuspended in an equal
volume of TES buffer. Vortexing and sonication were required to
break up the fibril pellet for a homogenous mixture of collagen.
The homogenous collagen solution was split into 25 mL aliquots
for treatment.
To untreated samples, 25 mL water was added to the collagen
solution (NT). To peptidoglycan treated samples, 15 mL water and
10 mL synthetic peptidoglycan (1.83 mg/mL) was added to the
collagen solution (DS-SILY). The collagen solutions were
incubated for 1 hour at room temperature to allow binding.
Samples were then pelleted by centrifugation at 15,000 rpm for 5
minutes and the supernatant was removed.
The degradation buffer was made within 1 hour of collagen
degradation studies. To the tris buffer, APMA (amino-phenyl
mercuric acetate) (3.5 mg/mL in 0.1 M NaOH) was added to a
final concentration of 1 mM APMA. HCl (1 M) was added at one
tenth the amount of APMA solution to maintain pH at 7.6.
Collagen pellets were resuspended in 25 mL water and 25 mL
degradation buffer. To control samples, 1 mL 1X PBS was added,
and to the degradation samples, 1 mL MMP-1 or MMP-13
(0.2 mg/mL and 0.5 mg/mL, respectively) was added. Samples
were mixed by vortexing and were incubated at 32uC overnight,
then frozen until further testing.
Samples were run under reducing conditions on a 7.5% Precast
Polyacrylamide gel (Biorad Tris 7.5% Mini-PROTEAN TGX
Precast Gel) at 200V. Protein in the gel was stained with
Coomassie Orange for 45 minutes, rinsed twice with 7.5% acetic
acid, rinsed 5 minutes with water, and imaged using a trans-UV
source. Protein bands were analyzed using ImageJ software and
the percent degradation was determined by comparing the
intensity of the total intact bands including alpha 1, alpha 2,
and oligomer bands. Collagen bands in samples treated with
MMP-1 or with MMP-13, with or without prior peptidoglycan
incubation, were compared to those same bands in collagen
controls not treated with MMP.
Rat incisional model
For the animal study, HA was used as a viscous delivery vehicle
for the peptidoglycan. Peptidoglycan DS-SILY was dissolved in
the HA vehicle at a concentration of 0.5 mg/mL, a dose
approximately equal to 10 mM in which maximal binding to
collagen is achieved.[29]
Male Long-Evans rats were purchased from Harlan Labs (San
Diego, CA) and were handled according to approved Purdue
Animal Care and Use Committee (PACUC) protocol 08-111. Rats
were housed in individual cages and acclimated for 1 week prior to
surgery. At time of surgery, rats were anesthetized by chamber
Table 1. Comparison of effects of decorin and DS-SILY
peptidoglycan in wound healing.
Mechanism of Action Decorin Peptidoglycan
Incorporate bioactive GAG chain [15–17] [15–17]
Control collagen fibrillogenesis [4,6,8,10,39,43] [5]
Enhance mechanical strength [5,6,8,10] [5]
Prevent MMP-mediated collagen
degradation
[18] Present work
Inhibit TGFb activity [22,25–27,44]
doi:10.1371/journal.pone.0022139.t001
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aseptically prepared. A single 4 cm longitudinal incision was made
through the skin and panniculus muscle along the dorsal spine. A
single dose of 250 mL treatment (no treatment (NT), HA, or DS-
SILY) was applied to the incision and the wound was closed by
simple interrupted absorbable sutures. Each treatment group
contained 3 rats for each time point.
Following surgery the rats recovered in their individual cages
and were given two injections of buprenorphine for pain. The rats
were observed daily and one rat was replaced due to complications
from self mutilation 24 hours after surgery.
At 3, 7, 10, 14, and 21 days, three rats in each group were
euthanized and a necropsy was performed. The back was shaved
and the incision was photographed. The skin containing the
healing incision was then excised and cut into eight 4 mm strips
perpendicular to the incision using a custom cutting device with
fixed blades. Alternate skin samples were immediately fixed in
10% neutral buffered formalin for histological analysis or were
placed in cold 1xPBS and immediately tested for tensile strength.
Tensile strength testing
The skin samples were loaded into the grips of a mechanical
testing system (Test Resources, model:100P/Q) such that the
incision line was orthogonal to the direction of tension. The grips
were set at a distance of 0.5 in and the scar was centered between
the grips. Samples were then loaded under tension at a rate of
5 mm/min to failure. The ultimate tensile strength at failure
(breaking strength) was recorded.
Histological evaluation
Formalin preserved skin samples were routinely processed and
sectioned for H&E and Masson’s Trichrome staining. H&E
stained samples were examined for inflammation by a board
certified pathologist using a scale adapted from Simhon and
coworkers, which includes evaluation of re-epithelization in the
form of hyperplasia, the degree and type of inflammatory cells
present, the appearance of fibroblasts and foreign body giant cells,
and the presence of granulation tissue.[30] Trichrome stained
images were scanned and the wound area was quantified using
ImageJ software. The granulation tissue was defined by charac-
teristic immature collagen with parallel orientation and dense
packing, described by Beausang and coworkers.[31] The total area
composed of this granulation tissue was traced and quantified
Transmission electron microscopy (TEM)
Histological samples were further processed for TEM imaging.
Slides of sections stained with Masson’s Trichrome were used to
identify and trim the paraffin tissue block to contain only the area
of the healing incision. Samples were deparaffinized by incubating
in toluene for 3 hours. Samples were embedded and cut 0.5 mm
deep, horizontal to the epidermal surface. Cross sections of
collagen fibrils were imaged using an FEI/Philips CM-10
transmission electron microscope (FEI Company, Hillsboro, OR)
using an accelerating voltage of 80 kV and at a magnification of
52 K. Three images were taken of each wound from each rat. The
diameter of each fibril in each image was measured using ImageJ
software.
Visible scar assessment
To evaluate visible scarring at 21 days, rats (n=9 rats per
group) were shaved and incisions were photographed. Photo-
graphs were taken using a camera stand with a fixed distance,
external lighting, and included ruler for scale. The digital images
were loaded into ImageJ software and five observers were trained
to trace visually scarred areas using the line tool. If the visible scar
was not continuous, the length of each scar segment was added
together to find a total visible scar length. Overall trends between
treatment types was the same for each observer, however the raw
values obtained for measured visible scar varied by observer. In
order to account for these differences, lengths were normalized to
untreated wounds for each observer and percent increase/
decrease over untreated wounds was compared. In this way,
measurements from each observer could be combined for analysis.
Inter-observer variability was small when comparing these
normalized values for scar length.
Statistics
All observers were blinded to treatment type. The breaking
strength, wound area, and visible scar length were compared on 3
levels: no treatment, HA control, and DS-SILY. The TEM
analysis was performed on these 3 levels and compared to intact
skin. Quantitative data was normally distributed and statistics were
analyzed by ANOVA using Design Expert software (StatEase,
Minneapolis, MN). Results are presented as average + S.D. and
significance was set by a=0.05.
Results
In Vitro collagen degradation
Peptidoglycan was added to collagen fibrils and then degrada-
tion by MMPs was assessed. As shown in Figure 1, the alpha 1
and alpha 2 chains of type I collagen and the heavier oligomer
bands are considered to be intact collagen and are indicated above
the dotted line. Degraded collagen, as indicated by smaller
molecular weight bands, appears below the line. Columns 1 and 4
depict collagen that was not subjected to degradation with either
MMP. The intensity of the intact bands (alpha 1, alpha 2, and
oligomer bands) in these lanes was used as a baseline. MMP
treatment (columns 2 and 5) degrades intact collagen and results in
the presence of smaller molecular weight degradation bands, and
correspondingly less intense intact bands. The intensities of the
intact bands were measured and revealed that MMP-1 degraded
18% of the intact bands, while MMP-13 degraded 55% of the
intact bands. Incubating the collagen with DS-SILY prior to
MMP treatment decreased degradation of the intact collagen
bands to 1% with MMP-1 and 15% with MMP-13 (columns 3 and
6). A separate study was performed in which DS-SILY was added
to untreated collagen at the same time as MMP-1 or MMP-13 to
verify that DS-SILY itself did not inhibit MMP activity (data not
shown).
Tensile strength
All of the rats recovered from surgery and survived to the time
of necropsy. There was no evidence of incisional infection or self-
mutilation. From 3 to 21 days, all wounds became progressively
stronger; however, there were no significant differences between
the treatment groups at 3, 7, 10, or 14 days (data not shown). At 21
days, the DS-SILY treated wounds were significantly stronger than
untreated (NT) or HA treated wounds (Figure 2). HA treatment
showed a modest, but not significant, increase in wound strength
over untreated wounds.
Histologic evaluation
There were no notable differences in the inflammatory response
between peptidoglycan-treated wounds and control wounds (data
not shown), indicating that the peptidoglycan did not cause any
adverse tissue reaction in the healing incision. Representative
Synthetic Peptidoglycans in Dermal Scarring
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are shown in Figure 3. The 21-day samples were trichrome
stained and the total area of granulation tissue was measured,
showing that incisions receiving peptidoglycan treatment had
significantly less granulation tissue than untreated wounds
(Figure 3). These results were confirmed using a qualitative
scoring method that has been used to evaluate collagen
organization, maturity, and density; [31] the scores followed the
same trends as for total granulation tissue area (data not shown).
Collagen fibril diameter
Sections of uninjured skin and the healing incisions at 21 days
post injury were processed for TEM and assessed for collagen fibril
diameter. Figure 4 shows representative images of cross sections
of collagen fibrils and histograms of the collagen fibril diameters
from each group of rats and from intact skin. Each graph inset
indicates the treatment type, average fibril diameter, and range of
fibril diameters (nm). Untreated wounds and HA control wounds
contained collagen fibrils with a wide range of diameters.
Treatment with DS-SILY resulted in collagen fibril diameter
and distribution similar in appearance to intact skin.
Visible scar
Figure 5 shows the visual scar length remaining 21 days after
surgery. The HA treated wounds showed significantly less visible
scar compared to untreated wounds. The peptidoglycan (DS-
SILY) treated wounds showed significantly less visible scar length
compared to both the untreated wounds and wounds receiving the
HA control.
Discussion
The native proteoglycan, decorin, plays a critical role in tissue
healing and in collagen organization.[6,9–11] Because decorin is
difficult to manufacture and its use limited, we have designed a
synthetic collagen-binding peptidoglycan which mimics, in part,
the functions of decorin (Table 1). The aim of this study was to
investigate the ability of the synthetic peptidoglycan DS-SILY to
inhibit MMP-mediated collagen degradation, and to assess the
resulting effects on dermal healing in the rat model.
Previously, our group reported the ability of DS-SILY to
modulate collagen fibril organization and increase the stiffness of
collagen gels in a manner similar to decorin.[5] Recently, Geng
and coworkers showed that native proteoglycans, including
decorin, fibromodulin, and lumican, protect collagen from MMP
degradation. Additionally, other PGs such as aggrecan play a
protective role against enzymatic degradation of the ECM. We
hypothesized that the synthetic peptidoglycan would have a similar
effect to native PGs in protecting collagen from degradation
against collagenases.[18] There are numerous MMPs involved in
the wound healing process. MMP-1 and MMP-13, which are
upregulated following injury, cleave intact collagen.[19,32–34]
The degraded collagen is then replaced with new collagen,
increasing granulation tissue volume and thus giving rise to a more
visible scar. Like native decorin, the synthetic peptidoglycan
prevents MMP-1 and MMP-13 mediated collagen degradation by
binding to collagen fibrils and providing a protective mask.[18,29]
Other MMPs, including MMP-8, are upregulated both in normal
healing and non-healing wounds, and the ability of a peptidogly-
can to protect collagen from degradation by these other MMPs is
currently under investigation.[19,20,35] Additionally, the concen-
tration of MMPs used in this study did not fully degrade the
collagen. The ability of the peptidoglycan to protect collagen from
higher concentrations of the MMPs will also be examined in future
studies.
Because the synthetic peptidoglycan DS-SILY inhibited MMP
collagen degradation in vitro, coupled with its demonstrated ability
to modulate collagen organization, we further investigated its
application in healing of dermal wounds. Incisional wounds were
created in rats, and the effects of the peptidoglycan on wound
healing were studied over 21 days. HA was used as a viscous
delivery vehicle so that the peptidoglycan would remain in place
allowing time for the peptidoglycan to bind to exposed collagen
while the wound was sutured. HA has been suggested to enhance
Figure 1. Collagen degradation by MMP. Intact collagen bands,
shown above the dotted line, were quantified and used to determine
the amount of collagen degraded, while collagen degradation products
appear below the dotted line. Collagen degradation with MMP-1 was
decreased with pre-incubation of DS-SILY from 18% to 1% (columns 2
and 3). Collagen degradation with MMP-13 was decreased with pre-
incubation of DS-SILY from 55% to 15% (columns 5 and 6). Intact
collagen not incubated with MMP-1 or MMP-13 (columns 1 and 4) was
used for comparison.
doi:10.1371/journal.pone.0022139.g001
Figure 2. Tensile Strength. Mean breaking strength of healed
incisions from each group of rats 21 days after surgery. ** denotes that
DS-SILY treated wounds were significantly stronger than both non
treated controls (NT) (p,0.001) and those receiving the HA excipient
(HA) (p=0.0178). n=12 tissue samples (3 rats in each group).
doi:10.1371/journal.pone.0022139.g002
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through its host of biochemical and biomechanical functions, and
as such, was chosen over other relatively inert excipients such as
pluronic.[36,37] Our study included both HA and untreated
control groups for comparison.
Collagen organization in the incisional scar was evaluated
histologically and by TEM. By both measures, peptidoglycan
treated wounds resulted in improved collagen morphology, with
uninjured skin tissue used as a standard. Histological analysis
revealed that the total area of granulation tissue in wounds treated
with peptidoglycan was significantly reduced compared to wounds
that were not treated. These results support the hypothesis that by
inhibiting MMP mediated collagen degradation at the injury site,
the synthetic peptidoglycan DS-SILY decreases the total amount
of granulation tissue.
TEM analysis revealed that while the HA treated wounds
contained collagen fibrils with the smallest average diameter, the
distribution of diameters in these wounds was spread with some
collagen fibrils over 200nm. Only wounds that were not treated
contained such large collagen fibrils, and a similar wide distribution
of fibril diameters. In contrast, the peptidoglycan treated wounds
did not contain any of these abnormally large fibrils and had a
distribution of fibril diameters more closely resembling that of
uninjured skin. These results corroborate our previous in vitro
studies and indicate that the synthetic peptidoglycan regulates
collagen organization and prevents lateral aggregation of collagen
fibrils in a manner similar to decorin.[5,12]
Scar tissue is weaker than healthy uninjured skin, which is a
consequence of immature collagen with nonuniform architecture
and organization.[38] Therefore the breaking strength of the scar
is an objective and quantifiable measure of tissue organization.
Peptidoglycan treated wounds had increased breaking strength
compared to untreated and HA control wounds, supporting the
histological and TEM data, and demonstrating a functional
consequence of improved collagen organization and decreased
scar tissue in peptidoglycan treated wounds.
Visible scarring on the skin surface is of high patient concern.
Our results demonstrated an improved cosmetic outcome with
peptidoglycan treatment and positively correlated with decreased
granulation volume seen histologically. Visible scarring in rats is
apparent by the lack of hair and a pale and somewhat shiny
epidermis. Since the peptidoglycan functions by regulating
collagen architecture and by inhibiting MMP mediated degrada-
tion of intact collagen, it is likely that decreased visible scarring is a
result of decreased granulation volume rather than a restoration of
all of the components of healthy skin including hair follicles. While
animal models are somewhat limited for assessing dermal scarring,
decreasing granulation tissue volume in human skin is likely to
have a similar positive impact on cosmetic outcome.
For this study, HA was used as a viscous excipient for delivery of
DS-SILY. HA treated control wounds showed trends towards
increased breaking strength, decreased wound area, and improved
histological evaluation over the untreated incisions. There was a
significant improvement in visible scarring and these results may
Figure 3. Histology. Representative Mason Trichrome stained microscopic sections of healed incisions in rats at 21 days. Arrows indicate the outer
limit of the granulation tissue area with no treatment (NT), HA excipient (HA), and peptidoglycan-treated wounds (DS-SILY). In each group, note the
marked differences in collagen organization and maturity in the granulation tissue area. The area of granulation tissue in each image was measured in
ImageJ. * denotes that DS-SILY treatment resulted in significantly smaller wound areas as compared to untreated wounds (NT) (p=0.0109). n=11
tissue samples.
doi:10.1371/journal.pone.0022139.g003
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healing. Some investigations suggest that the water inclusion
provided by HA can facilitate the migration of cells to the wound
area and facilitate movement of newly synthesized collagen
molecules and fibrils.[39] Our study shows that while HA offered
some benefits to the healing wound, it does not affect the
uncontrolled lateral aggregation of collagen fibrils that leads to
nonuniform architecture and organization. The increased hydra-
tion with HA, combined with the ability of DS-SILY to both
protect collagen from degradation and control collagen architec-
ture, may have acted synergistically to prevent dermal scarring.
Further studies are needed to determine the ideal excipient for DS-
SILY and to isolate the unique mechanisms of action of the
peptidoglycan.
Other work in dermal healing has highlighted the inflammatory
aspect of wound healing and its contribution to scar formation. In
Figure 4. Collagen Fibril Diameter by TEM. Representative TEM images of collagen fibrils from wounded areas and histograms of fibril
diameters. There was a broader distribution of collagen fibril diameters in untreated and HA treated incisions. The DS-SILY treated wounds more
closely resembled intact skin with a narrower distribution of collagen fibril diameters. Graph inserts indicate treatment type, average fibril diameter
(nm), and the total range of fibril diameters (nm).
doi:10.1371/journal.pone.0022139.g004
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TGFb1 during the inflammatory phase of wound healing in order
to reduce scar formation.[21,23–25,27,40–42] The core protein of
decorin is able to bind to and inhibit TGFb1, and could be a
possible treatment for scar reduction by this mechanism. The
synthetic peptidoglycan, DS-SILY, while modeled to mimic many
of the functions of decorin, does not contain the large core protein
of decorin, and apparently cannot operate by inhibiting TGFb1i n
the wound bed. The peptidoglycan does mimic many of the other
functions of decorin that may play a role in dermal healing, and
offers advantages over native decorin in its ease and low cost of
manufacturing.
Recognizing the limitations of using normal animal models to
study wound healing, the results of this study warrant further
investigation. Here a single dose of peptidoglycan applied at the
time of injury and immediately prior to suturing resulted in
improved dermal healing as defined by greater tensile strength,
improved collagen organization, and improved visible scar 21 days
following a linear incision in the rat. This peptidoglycan may offer
a feasible approach for scar mitigation and further investigation for
human use is warranted.
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